Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy Plus Nimotuzumab or Cisplatin in Low-risk Locoregionally Advanced Nasopharyngeal Carcinoma
NCT04456322Phase 3Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2020
- Primary completion
- May 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised trial of nimotuzumab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 2 years. Started Aug 2020; status: active, not recruiting.
02
Drugs
nimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04456322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04456322.